Perspective Therapeutics, Inc. CATX
2.52
0.02
0.80%
as of 25 Sep
- Market cap
- $285.4M
- P/E
- 0.0×
Follow CATX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(37.08%) | (41.44%) | (35.16%) | (39.50%) | |
| (30.85%) | (33.92%) | (30.03%) | (33.14%) | ||
ROIC |
(106.51%) | (111.14%) | (96.09%) | (88.41%) | |
Return on Tangible Assets |
(47.61%) | (52.53%) | (33.04%) | (37.23%) | |
Average Days of Receivables |
60.78 | 2.48 | 34.26 | 240.06 | |
Free Cash Flow per Share |
(1.43) | (1.29) | (1.04) | (1.00) | |
Free Cash Flow |
(106.39) | (95.23) | (107.32) | (121.19) | |
Capital Expenditures |
(21.95) | (12.75) | (14.95) | (28.12) | |
Piotroski F-Score |
1.00 | 2.00 | 2.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(20.20%) | (23.34%) | (14.90%) | (16.55%) | |
Accounts Receivable Turnover |
5.43 | 14.49 | 9.09 | 1.66 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
5,969.67% | 9,526.58% | 14,766.18% | 23,515.65% | |
Selling, General and Administrative Expense of Revenue |
2,932.84% | 3,420.02% | 4,753.40% | 7,203.42% | |
Share Based Compensation of Revenue |
810.88% | 1,014.25% | 1,524.43% | 2,460.64% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.80 | 0.80 | 0.83 | 0.80 | |
Depreciation/Fixed assets |
0.37 | 0.01 | 0.02 | 0.02 | |
Capex/Depreciation |
(0.91) | (24.15) | (10.51) | (14.46) | |
Revenue per Share |
0.01 | 0.01 | 0.01 | 0.00 | |
Operating CF per Share |
(1.14) | (1.12) | (0.89) | (0.77) | |
Capex per Share |
(0.30) | (0.17) | (0.14) | (0.23) | |
Capex to Sales |
20.42 | 14.42 | 24.19 | 68.75 | |
Net Profit Margin |
(9,841.86%) | (11,665.27%) | (17,982.69%) | (28,467.97%) |
Columns are period end dates